Compare Divis Laboratories with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AUROBINDO PHARMA DIVIS LABORATORIES/
AUROBINDO PHARMA
 
P/E (TTM) x 57.5 7.5 764.4% View Chart
P/BV x 13.2 1.8 732.8% View Chart
Dividend Yield % 0.4 0.6 72.9%  

Financials

 DIVIS LABORATORIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-21
AUROBINDO PHARMA
Mar-21
DIVIS LABORATORIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs3,9131,023 382.5%   
Low Rs1,824333 547.2%   
Sales per share (Unadj.) Rs262.5422.8 62.1%  
Earnings per share (Unadj.) Rs74.792.0 81.3%  
Cash flow per share (Unadj.) Rs84.4110.0 76.7%  
Dividends per share (Unadj.) Rs20.004.00 500.0%  
Avg Dividend yield %0.70.6 118.2%  
Book value per share (Unadj.) Rs350.1374.3 93.5%  
Shares outstanding (eoy) m265.47585.94 45.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x10.91.6 681.2%   
Avg P/E ratio x38.47.4 520.4%  
P/CF ratio (eoy) x34.06.2 551.3%  
Price / Book Value ratio x8.21.8 452.1%  
Dividend payout %26.84.3 615.2%   
Avg Mkt Cap Rs m761,517397,398 191.6%   
No. of employees `000NANA-   
Total wages/salary Rs m8,25835,350 23.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m69,694247,746 28.1%  
Other income Rs m6273,809 16.5%   
Total revenues Rs m70,321251,555 28.0%   
Gross profit Rs m28,61181,480 35.1%  
Depreciation Rs m2,55610,554 24.2%   
Interest Rs m21745 2.8%   
Profit before tax Rs m26,66073,990 36.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6,81820,098 33.9%   
Profit after tax Rs m19,84353,892 36.8%  
Gross profit margin %41.132.9 124.8%  
Effective tax rate %25.627.2 94.1%   
Net profit margin %28.521.8 130.9%  
BALANCE SHEET DATA
Current assets Rs m67,906198,235 34.3%   
Current liabilities Rs m17,284106,652 16.2%   
Net working cap to sales %72.637.0 196.5%  
Current ratio x3.91.9 211.4%  
Inventory Days Days1019 49.6%  
Debtors Days Days87852 1,701.2%  
Net fixed assets Rs m45,963135,778 33.9%   
Share capital Rs m531586 90.6%   
"Free" reserves Rs m92,415218,713 42.3%   
Net worth Rs m92,946219,299 42.4%   
Long term debt Rs m01,684 0.0%   
Total assets Rs m113,869334,013 34.1%  
Interest coverage x1,270.5100.3 1,266.4%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.7 82.5%   
Return on assets %17.416.4 106.6%  
Return on equity %21.324.6 86.9%  
Return on capital %28.733.8 84.9%  
Exports to sales %053.8 0.0%   
Imports to sales %18.816.4 114.9%   
Exports (fob) Rs mNA133,248 0.0%   
Imports (cif) Rs m13,12740,615 32.3%   
Fx inflow Rs m58,877133,248 44.2%   
Fx outflow Rs m13,34144,946 29.7%   
Net fx Rs m45,53688,302 51.6%   
CASH FLOW
From Operations Rs m19,46933,289 58.5%  
From Investments Rs m7515,987 12.5%  
From Financial Activity Rs m-349-13,648 2.6%  
Net Cashflow Rs m19,87225,831 76.9%  

Share Holding

Indian Promoters % 52.0 48.8 106.5%  
Foreign collaborators % 0.0 3.1 -  
Indian inst/Mut Fund % 37.1 37.2 99.5%  
FIIs % 20.7 21.7 95.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.1 48.2 99.8%  
Shareholders   223,403 329,940 67.7%  
Pledged promoter(s) holding % 0.0 24.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   JUBILANT PHARMOVA   GRANULES INDIA  BHARAT PARENTALS  MANGALAM DRUGS  GLENMARK LIFE SCIENCES  



Today's Market

Sensex Snaps 2-Day Losing Streak, Zooms 887 Points, Nifty Settles Above 17,150; Tata Steel, Axis Bank Top Gainers(Closing)

Indian share markets witnessed positive trading activity throughout the day today and ended on a strong note.

Related Views on News

DIVIS LABORATORIES 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of DIVIS LABORATORIES for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

AUROBINDO PHARMA Announces Quarterly Results (1QFY22); Net Profit Down 2.0% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (down 2.0% YoY). Sales on the other hand came in at Rs 57 bn (down 3.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

Aurobindo Pharma's Stock Falls After Profits Decline 7% (Views On News)

Jun 1, 2021

Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

India's Top 5 Monopoly Stocks to Watch Out for(Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.

The Biggest Winners and Losers in India's Transition to Electric Vehicles(Profit Hunter)

Nov 26, 2021

How India's EV transition could be a major headwind for the incumbents.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Dec 7, 2021 03:36 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS